Historically, manufacturers have been challenged by some of the 340B program nuances and, with the expansion of the Medicaid Drug Rebate program under Affordable Care Act (ACA), manufacturers are likely to see the following challenges grow in volume.
Accurate accounting from Covered Entities (CE) for refund payments
Health Resources and Services Administration (HRSA) has increased scrutiny around the 340B program and are conducting more targeted audits, CEs are performing internal audits to better understand any non-compliance and are taking steps to “self-disclose†non-compliance activity and proactively sending refund payments to manufacturers. Do you know how to account for the refunds?
Avoid duplicate payments (340B pricing & Medicaid Rebates) to Covered Entities
The 340B program prohibits duplicate discounts and CEs must have a process in place to prevent duplicate discounts (double dip). Are you paying twice?
“GPO Prohibition†for selective Covered Entities
Disproportionate share hospitals (DSH) and other selective facilities types participating in 340B may not “obtain covered outpatient drugs through a group purchasing organization (GPO) or other group purchasing arrangement.†Are you having membership woes?
If you are seeking to better understand the impact the 340 B program has on your organization and gain realistic approaches to managing these challenges, please register for this webinar.
Presented by
Steve Medina,
Vice President, Covance Market Access Services
Mr. Medina has led the Covance Managed Market Services business since, July 2012. He has been a consultant for 24 years, 20 of them with healthcare manufacturing, specializing in on-going service solutions (system and business processing), account management, and systems implementation. Mr. Medina has extensive experience with contract management and sales and marketing.
Before joining Covance, Mr. Medina worked for CSC as a Partner Level 2 where he was a Solution Leader for CSC's HAALO (Healthcare Applications Augmentation and Leading-Edge Outsourcing) practice; IMS Health, where he ran the Delivery Services organization and was responsible for providing Managed Market Solutions; and Highpoint, where he was the Vice President of Managed Service.
Mr. Medina has demonstrated the ability to work with clients to help them identify their needs to create a solution that meets their requirements as well as their budgets. He has been part of many large pharmaceutical firms' projects and service agreements from start to finish.
Mr. Medina received his Bachelor of Science in Computer Science from the Rensselaer Polytechnic Institute located in upstate New York.
John Giles, Jr.,
Director, Covance Market Access Services
John is a Director in Managed Market Services and leads the business development in Covance Managed Market Services business. He has been in various roles for 25 years in the healthcare industry, specializing in a wide variety of data solutions, account management, analytics and enterprise wide systems.
He has worked for Roche and Johnson & Johnson in sales and marketing, contracting and sales operations. Before joining Covance, John was an Account Executive for IMS Health selling the portfolio of products and services. At IMS Health, John worked closely with Fortune 50 companies to help create marketing strategies and create solutions to wide variety of issues.
